Ensitrelvir

Summary

Ensitrelvir (CHEMBL5183847) is a phase-3 clinical-stage small molecule (ATC J05AE16); indicated across 5 conditions including severe acute respiratory syndrome and viral infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J05AE16
• Indications: 5 conditions
• Clinical trials: 7
• Chemistry: 531.9 Da · C22H17ClF3N9O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5183847
Name	Ensitrelvir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	162533924
ATC	J05AE16
Molecular formula	C22H17ClF3N9O2
Molecular weight	531.9
InChIKey	QMPBBNUOBOFBFS-UHFFFAOYSA-N

SMILES: CN1C=C2C=C(C(=CC2=N1)Cl)NC3=NC(=O)N(C(=O)N3CC4=CC(=C(C=C4F)F)F)CC5=NN(C=N5)C

IUPAC name: 6-[(6-chloro-2-methylindazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4-dione

Also known as: Ensitrelvir, S-217622, ENSITRELVIR

Parent form; salt/anhydrous children: CHEMBL5185221

Patent coverage: 65 distinct patent families (102 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 74 (73%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CoV 3C-like (main) protease	Inhibition	7.89

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Replicase polyprotein 1ab.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0DTD1	10.89	IC50	0.01	nM	CHEMBL_ACT_24695396
P0DTD1	8.22	Kd	6	nM	CHEMBL_ACT_29060402
P0DTD1	8	IC50	10	nM	CHEMBL_ACT_24771740

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
viral infectious disease	3	MONDO:0005108	EFO:0000763
liver disorder	1	MONDO:0005154	EFO:0001421
kidney disorder	1	MONDO:0005240	EFO:0003086

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05305547	PHASE3	COMPLETED	A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
NCT05897541	PHASE3	COMPLETED	Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
NCT05041907	PHASE2	RECRUITING	Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
NCT06161688	PHASE2	ACTIVE_NOT_RECRUITING	Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
NCT05363215	PHASE1	COMPLETED	A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
NCT05409911	PHASE1	COMPLETED	A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
NCT06775730	PHASE1	COMPLETED	A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).